- The Washington Times - Saturday, February 11, 2006

A rare bit of good news recently trickled out about Medicare’s new prescription-drug entitlement. The entitlement will cost $678 billion over 10 years, rather than the $737 billion previously projected.

The reason for this “savings”? It’s partly that fewer seniors have signed up for the entitlement than the 33 million the government expected. Out of the 24 million now enrolled, only 3.6 million actually “signed up” — the rest had no choice.

But this shortfall is really no surprise. So far, the program has been a disaster.

“Pharmacists decry Medicare chaos,” blared a recent headline in the Daily Tennessean. The article beneath is typical of those published after the new entitlement took effect: pharmacists spending hours on hold with the government only to be cut off, seniors having to pay thousands more than expected for their prescriptions, and some even going without drugs.

Those seniors who have suffered most are the so-called “dual eligibles,” needy seniors who had previously had drug coverage under their states’ Medicaid programs. They had no choice: On Jan. 1, they were dumped into the Medicare drug entitlement.

The Tennessean reports this has been “an out-and-out catastrophe for the poor.” As an advocate for seniors told the New York Times, “All this is doing is harming the people who had coverage — America’s most vulnerable citizens.”

With all these horror stories in the press, better-off seniors, who can choose whether to join the new entitlement, have avoided signing up. Thus, the savings.

The rest of the savings come from the part of the entitlement most maligned by its political opponents. Because the entitlement relies on the market and insurance companies to provide drug benefits, instead of the government, competition has driven premiums 20 percent lower than expected.

That’s the good news. The bad news is that all this chaos, suffering and catastrophe were predictable. Indeed, Robert Moffit of the Heritage Foundation predicted it in a policy paper published last June:

“Millions of seniors will lose their existing drug coverage, have their existing coverage degraded, or find themselves struggling with congressionally-engineered gaps in drug coverage. Many who find themselves in these gaps will be among the sickest and most vulnerable members of the Medicare population.”

That Heritage paper said the new entitlement is a “massive new experiment in central planning.” We should have learned over the last century that central planning doesn’t work.

This mess was avoidable. Back in 2003, when Congress began working on the drug entitlement, it started with a real problem: Some seniors couldn’t afford prescription drugs, harming their health and ultimately driving up the cost of Medicare.

The obvious solution was to target aid to those seniors unable to afford drug coverage. Most seniors already have it (often through former employers), and this coverage tends to be more generous than what Medicare offers.

The neediest seniors, along with many in nursing homes, already had drug coverage through Medicaid. This left a narrow group who couldn’t afford coverage and weren’t already receiving it from Medicaid. Congress could have reached them with a simple direct subsidy.

Instead, Congress created a universal entitlement for every senior in the country. The cost is massive — even with the latest savings, $678 billion over 10 years isn’t exactly peanuts — and the program may never work right.

By all appearances, the drug benefit passed in 2003 is so unwieldy and complicated the Medicare bureaucracy can’t safely administer it.

And the worst is yet to come. While the initial kinks may be ironed out with no substantial reform, the massive drug entitlement will never work efficiently. Meanwhile, more retirees will be dumped into the entitlement as their former employers use it as an excuse to discontinue drug coverage. And as the year progresses, seniors will fall into the entitlement’s notorious “doughnut hole,” where they must pay for all drugs out-of-pocket — as if they had no coverage at all.

Ironically, the drug entitlement failure has emboldened those who seek a larger role for government in health care. Psychologists describe this kind of response as “cognitive dissonance,” when a belief is often held so firmly no contrary evidence can budge it. Judging by the amount of time members of Congress and the administration have spent touting the new entitlement, almost all Washington suffers from this disorder.

Andrew M. Grossman is a senior Web editor at the Heritage Foundation.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide